A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes

Edouard L. Fu, Julianna Mastrorilli, Katsiaryna Bykov, Deborah J. Wexler, Alexander Cervone, Kueiyu Joshua Lin, Elisabetta Patorno, Julie M. Paik

Kidney International · 2023 · 19 citations · 29 references

DOIFull text

Open access

Concepts

References

29